10-QPeriod: Q2 FY2023

CVS HEALTH Corp Quarterly Report for Q2 Ended Jun 30, 2023

Filed August 2, 2023For Securities:CVS

Summary

CVS Health Corporation reported total revenues of $88.9 billion for the three months ended June 30, 2023, an increase of 10.3% compared to the prior year, driven by growth across all segments. Net income attributable to CVS Health was $1.9 billion, a decrease of 37.2% from the prior year, primarily impacted by increased operating expenses, restructuring charges, and acquisition-related costs. The company completed significant acquisitions of Oak Street Health and Signify Health during the period, which contributed to revenue growth but also increased operating expenses and debt. Despite a challenging quarter in terms of net income, the company generated strong operating cash flow and maintained a solid liquidity position. Key strategic initiatives include expanding value-based care through acquisitions and streamlining operations. While revenue growth remains robust, investors should monitor the impact of integration costs, increased interest expenses, and ongoing legal and regulatory matters, particularly those related to opioids and PBM practices, which could affect future profitability.

Financial Highlights

56 data points
Beta

Revenue

$88.92B

39.8% Gross Margin

Net Income

$1.91B

2.2% Net Margin

EPS (Diluted)

$1.48

Total Assets

$250.07B

Cash & Equivalents

$13.81B

Free Cash Flow

$5.32B

Financial Statements
Beta
Revenue$88.92B
Cost of Revenue$53.54B
Gross Profit$35.38B
Operating Expenses$85.69B
Operating Income$3.23B
Interest Expense$686.00M
Net Income$1.91B
EPS (Basic)$1.48
EPS (Diluted)$1.48
Shares Outstanding (Basic)1.28B
Shares Outstanding (Diluted)1.29B

Key Highlights

  • 1Total revenues increased by 10.3% to $88.9 billion for the quarter, reflecting growth across all segments.
  • 2Net income attributable to CVS Health decreased by 37.2% to $1.9 billion, impacted by significant charges and acquisition-related costs.
  • 3The company successfully acquired Oak Street Health for $9.7 billion and Signify Health for $7.4 billion, strengthening its Health Services segment.
  • 4Operating income declined 30.7% year-over-year, influenced by a $496 million restructuring charge and acquisition integration costs.
  • 5Operating cash flow was strong, with $13.3 billion generated in the first six months of 2023, an increase of 48.2% year-over-year.
  • 6Long-term debt increased significantly to fund acquisitions, with total borrowings reaching $61.4 billion.
  • 7The company continues its share repurchase program, with $10 billion authorized and $4.5 billion remaining as of June 30, 2023.

Frequently Asked Questions

The acquisitions of Oak Street Health and Signify Health, completed in March and May 2023 respectively, contributed to the significant increase in total revenues, particularly within the Health Services segment. However, these acquisitions also led to higher operating expenses due to integration costs and amortization of acquired intangible assets. The company also incurred additional debt to finance these transactions, increasing interest expense.

The decrease in net income was primarily driven by a substantial increase in operating expenses, which included a $496 million restructuring charge in the current quarter, acquisition-related transaction and integration costs, and the absence of a $225 million gain on the sale of PayFlex from the prior year. Additionally, increased interest expense from higher debt levels impacted profitability.

CVS Health significantly increased its long-term debt to finance the acquisitions of Oak Street Health and Signify Health. The company issued approximately $10.9 billion in new senior notes during the first six months of 2023. Despite the increased debt burden, the company generated strong operating cash flow, which is expected to help manage these obligations. The company's credit ratings remain investment grade ('Baa2' by Moody's and 'BBB' by S&P), with a 'Stable' outlook.

CVS Health faces several ongoing risks and challenges, including continued pharmacy reimbursement pressure, potential regulatory changes impacting PBM practices, and significant legal proceedings. Notably, the company has agreed to substantial settlements related to opioid litigation, though the ultimate impact may still differ from accruals. There are also ongoing investigations and litigation concerning PBM practices, drug pricing, and risk adjustment data submissions, which could result in further financial penalties or operational changes.